1Banehereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells[J]. Annual Review of Immunology,2000,18 : 767-811.
2Rescigno M. Dendritic cells in tolerance induction for the treatment of autoim- mune diseases[J]. European Journal of Immunology,2010, 40(8) : 2119- 2123.
3Lutz MB, Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T- cell cross-tolerance by dendritic cells [ J ]. European Journal of Immunology, 2009,39(9) : 2325-2330.
4Woltman AM, Massacrier C, de Fijter JW, et al. Corticosteroids prevent gen- eration of CD3~-defived dermal dendritic cells but do not inhibit Langerhans cell development[J]. Journal of Immunology,2002,168(12) : 6181-6188.
5Rozkova D, Horvath R, Bartunkova J, et al. Glucocortieoids severely impair differentiation and antigen presenting function of dendritic cells despite upregu- lation of Toll-like receptors[J]. Clinical Immunology,2006, 120(3) : 260-271.
6Hackstein H, Taner T, Zahorchak AF, et al. Rapamyein inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo[ J ]. Blood,2003,101 ( 11 ) : 4457-4463.
7Lee YR, Yang II-I, Lee YH, et al. Cyclosporin A and tacrolimus, but not ra- pamycin, inhibit MHC-restrieted antigen presentation pathways in dendritic cells[J]. Blood,2005, 105(10) : 3951-3955.
8Hart S, Kim K, Song Y, et al. Auranofin, an immunosuppressive drug, inhib- its MHC class I and MHC class II pathways of antigen presentation in dendritic cells [ J ]. Archives of Phartrm~al Research,2008,31 ( 3 ) : 370-376.
9MartIn-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming[J]. The Journal of Experimental Mediciae , 200 3 ,198 ( 4 ) : 615-621.
10Wu WL, Ho LJ, Chert PC, et al. lmmunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells[J]. Journal of Clinical Immunology,2011,31 (6) : 1065-1078.
2Zhang WX, Chen B, Jin Z, et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophe- nolic acid and its metabolites in Chinese renal transplant re- cipients[J]. Xenobiotica, 2008, 38 ( 11 ) : 1422-1436.
3Naesens M, KuyPers DR, Verbeke K, et al. Muhidrug re- sistance protein 2 polymorphisms influence mycophenolic acid exposure in renal allograft recipients [ J ]. Transplanta- tion, 2006, 82 (8):1074-1084.
4El-Sheikh AA, Koenderink JB, Wouterse AC, et al. Renal glucuronidation and muhidrug resistance protein 2-muhidrug resistance protein 4-mediated eitlux of mycophenolic acid: interaction with cyclosporine and tacrolimus [ J ]. Transl Res, 2014, 164(1) :46-56.
5Kim WJ, Lee JH, Yi J, eta/. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carhamazepine in patients with epilepsy [ J ]. Pha.ogenet Genomics, 2010, 20(4) :249-256.
6C, eng F, Jiao Z, Dan YJ, et al. The association of the UGT1A8, SLCOIB3 and ABCC2/ABCG2 genetic polymor- phisms with the pharmacokinetics of mycophenolic acid and its phenolic giucuronide metabolite in Chinese individuals [J]. Clin Chim Acta, 2012, 413(7-8) : 683-690.
7Miura M, Satoh S, Inoue K, et al. Influence of SLCOIBI, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycopim- nolic acid pharmacokinetics in Japanese renal transplant re- cipients [J]. Eur J Clin Pharmacol, 2007, 63(12) : 1161- 1169.
8Afsar NA, Haenisch S, Mateen A, et al. Genotype frequen- cies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemother- apy[J]. Basic Clin Pharmacol Toxicol, 2010, 107: 570- 576.
9Choi JH, Aim BM, Yi J, et al. MRIr2 haplotypes confer differential susceptibility to toxic liver in jury [ J ]. Phar-maogenet Genomies, 2007, 17(6) :403-415.
10Anderson PL, Lamba J,Aquilante CL, et al. Pharmacoge- netie characteristics of indinavir, zidovudine, and lamivudi- ne therapy in HIV-infeeted adults: a pilot study [ J ]. J Ac-quir lmmune Defic syndr, 2006, 42(4) :441--449.
